# CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes

Study · id `cardio:ct-nct05931276` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05931276](<https://clinicaltrials.gov/study/NCT05931276>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05931276

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2540 participants.

## Technical summary

Registry record NCT05931276. Randomized; no masking; primary purpose treatment. Start 2024-05-22 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2540 participants (planned count; ClinicalTrials.gov record NCT05931276, source copy `cardio:ctgov-nct05931276-2026-10-13`, retrieved 2026-10-26)
- Started: 2024-05-22 (actual) (ClinicalTrials.gov record NCT05931276, source copy `cardio:ctgov-nct05931276-2026-10-13`, retrieved 2026-10-26)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT05931276, source copy `cardio:ctgov-nct05931276-2026-10-13`, retrieved 2026-10-26)
- Completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT05931276, source copy `cardio:ctgov-nct05931276-2026-10-13`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05931276, source copy `cardio:ctgov-nct05931276-2026-10-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05931276-2026-10-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
- Acronym: BRAVO
- Condition: End-Stage Kidney Disease
- Condition: End-Stage Renal Disease
- Intervention (Drug): Metoprolol Succinate
- Intervention (Drug): Carvedilol
- Lead sponsor: VA Office of Research and Development
- Lead sponsor class: FED

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry intervention name matches this record: Carvedilol (`cardio:carvedilol`)
- Registry intervention is a member of this class by a sourced record link: Beta-blockers (drug class) (`cardio:beta-blockers`)
- Registry lists this organization as the lead sponsor: VA Office of Research and Development (`cardio:org-va-office-of-research-and-development`)

## Provenance

Content hash: 371fd29abde3e58bf16ee454c7e87cbb74290b385a3644f3b1cbce15a670acf4
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
